These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11694849)

  • 1. Impact of genotypic resistance testing on physician selection of antiretroviral therapy.
    Jones S; Klotman ME
    J Hum Virol; 2001; 4(4):214-6. PubMed ID: 11694849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
    De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
    HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
    Verhofstede C; Van Wanzeele F; Van Der Gucht B; Pelgrom J; Vandekerckhove L; Plum J; Vogelaers D
    J Med Virol; 2007 Sep; 79(9):1254-60. PubMed ID: 17607772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART.
    Monno L; Punzi G; Scarabaggio T; Saracino A; Brindicci G; Fiore JR; Iambrenghi OC; Di Stefano M; Pastore G; Angarano G
    J Med Virol; 2003 May; 70(1):1-9. PubMed ID: 12629636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.
    Delaugerre C; Morand-Joubert L; Chaix ML; Picard O; Marcelin AG; Schneider V; Krivine A; Compagnucci A; Katlama C; Girard PM; Calvez V
    Antivir Ther; 2004 Jun; 9(3):415-21. PubMed ID: 15259904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.